कनाडा - अंग्रेज़ी - Health Canada

sandoz canada incorporated - pemetrexed (pemetrexed disodium hemipentahydrate) - powder for solution - 500mg - pemetrexed (pemetrexed disodium hemipentahydrate) 500mg - antineoplastic agents

कनाडा - अंग्रेज़ी - Health Canada

sandoz canada incorporated - pemetrexed (pemetrexed disodium hemipentahydrate) - powder for solution - 1000mg - pemetrexed (pemetrexed disodium hemipentahydrate) 1000mg - antineoplastic agents

कनाडा - अंग्रेज़ी - Health Canada

apotex inc - pemetrexed (pemetrexed disodium) - powder for solution - 500mg - pemetrexed (pemetrexed disodium) 500mg - antineoplastic agents

कनाडा - अंग्रेज़ी - Health Canada

apotex inc - pemetrexed (pemetrexed disodium) - powder for solution - 100mg - pemetrexed (pemetrexed disodium) 100mg - antineoplastic agents

कनाडा - अंग्रेज़ी - Health Canada

jamp pharma corporation - pemetrexed (pemetrexed disodium) - powder for solution - 100mg - pemetrexed (pemetrexed disodium) 100mg

कनाडा - अंग्रेज़ी - Health Canada

jamp pharma corporation - pemetrexed (pemetrexed disodium) - powder for solution - 500mg - pemetrexed (pemetrexed disodium) 500mg

कनाडा - अंग्रेज़ी - Health Canada

accord healthcare inc - pemetrexed (pemetrexed disodium hemipentahydrate) - powder for solution - 100mg - pemetrexed (pemetrexed disodium hemipentahydrate) 100mg - antineoplastic agents

कनाडा - अंग्रेज़ी - Health Canada

accord healthcare inc - pemetrexed (pemetrexed disodium hemipentahydrate) - powder for solution - 500mg - pemetrexed (pemetrexed disodium hemipentahydrate) 500mg - antineoplastic agents

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

sandoz gmbh - pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesothelioma pemetrexed sandoz in combination with cisplatin is indicated for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer pemetrexed sandoz in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed sandoz is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

eli lilly netherlands - pemetrexed - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesotheliomapemetrexed lilly in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.pemetrexed lilly is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non small cell lung cancer other than predominantly squamous cell histology.